These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38798047)

  • 1. Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis.
    Lee BW; Lee JJ; Kim WU
    Korean J Intern Med; 2024 Sep; 39(5):833-844. PubMed ID: 38798047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study.
    Jeong S; Choi S; Park SM; Kim J; Ghang B; Lee EY
    Arthritis Res Ther; 2022 Jul; 24(1):180. PubMed ID: 35902964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs.
    Baker MC; Liu Y; Lu R; Lin J; Melehani J; Robinson WH
    JAMA Netw Open; 2023 Mar; 6(3):e233640. PubMed ID: 36939701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia.
    Fletcher A; Lassere M; March L; Hill C; Barrett C; Carroll G; Buchbinder R
    Rheumatology (Oxford); 2022 Oct; 61(10):3939-3951. PubMed ID: 35094044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting.
    Choi S; Ghang B; Jeong S; Choi D; Lee JS; Park SM; Lee EY
    Semin Arthritis Rheum; 2021 Aug; 51(4):685-691. PubMed ID: 34139521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subsequent biologic and targeted synthetic disease modifying anti rheumatic drugs after fulfilling difficult-to-treat rheumatoid arthritis criteria: a survival analysis.
    Novella-Navarro M; Ruiz-Esquide V; López-Juanes N; Chacur CA; Monjo-Henry I; Nuño L; Peiteado D; Villalba A; Fernández-Fernandez E; Sanz-Jardón M; Kafati M; Sanmartí R; Plasencia-Rodríguez C; Balsa A
    Clin Rheumatol; 2024 Sep; 43(9):2817-2823. PubMed ID: 39009920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries.
    Glintborg B; Di Giuseppe D; Wallman JK; Nordström DC; Gudbjornsson B; Hetland ML; Askling J; Grondal G; Sokka T; Provan SA; Michelsen B; Kristianslund EK; Dreyer L; Love TJ; Lindström U
    Ann Rheum Dis; 2023 Jun; 82(6):820-828. PubMed ID: 36813538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study.
    Scheepers L; Yang Y; Chen YL; Jones G
    Semin Arthritis Rheum; 2024 Feb; 64():152314. PubMed ID: 38029717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database.
    Lee MY; Shin JY; Park SY; Kim D; Cha HS; Lee EK
    Semin Arthritis Rheum; 2018 Feb; 47(4):485-491. PubMed ID: 28939234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic and targeted synthetic disease-modifying anti-rheumatic drugs improve body composition in rheumatoid arthritis patients more than conventional synthetic disease-modifying anti-rheumatic drugs: Results from the PRESENT study.
    Tada M; Matsumoto Y; Koike T; Mamoto K; Nakamura T; Anno S; Iida T; Goto H; Hidaka N
    Int J Rheum Dis; 2024 Oct; 27(10):e15371. PubMed ID: 39381837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
    Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
    Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life and disease activity of patients with rheumatoid arthritis on tofacitinib and biologic disease-modifying antirheumatic drug therapies.
    Boyadzhieva V; Tachkov K; Stoilov N; Mitov K; Stoilov R; Petrova G
    Rheumatol Int; 2022 Oct; 42(10):1775-1783. PubMed ID: 35759028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
    J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
    Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H
    Arthritis Res Ther; 2019 Apr; 21(1):91. PubMed ID: 30971306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice.
    Huss V; Bower H; Wadström H; Frisell T; Askling J;
    Rheumatology (Oxford); 2022 May; 61(5):1810-1818. PubMed ID: 34324640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
    Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
    Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry.
    Jung JY; Lee E; Kim JW; Suh CH; Kim HA
    Clin Exp Rheumatol; 2023 May; 41(5):1034-1041. PubMed ID: 36062753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review.
    Emery P; Pope JE; Kruger K; Lippe R; DeMasi R; Lula S; Kola B
    Adv Ther; 2018 Oct; 35(10):1535-1563. PubMed ID: 30128641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Shiba H; Son Y; Amuro H; Onishi A; Akashi K; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
    Arthritis Res Ther; 2020 Jun; 22(1):142. PubMed ID: 32539813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.